Clinical reviewer: Dr. Sarah Boss, MD

This guide is published by COGNIFUL, part of THE BALANCE GROUP. It compares selected Swiss pathways with our own overseas residential role. It is not an independent ranking of luxury clinics, and the listed services are not equivalent in purpose or access. The actual program, clinical team, admission criteria and payment arrangements should be confirmed directly.

Physical dependence can occur after regular prescribed benzodiazepine use. The joint guideline distinguishes it from a substance use disorder, which involves a harmful pattern such as impaired control and continued use despite consequences. A person may need substantial support without having misused the medicine. Treatment should recognize the medical issue accurately rather than require an addiction label as the price of receiving help. [1]

At the same time, an original prescription does not rule out later harmful use. Ask the clinician to explore actual use, additional supplies, effects on daily functioning and the person’s ability to follow an agreed plan. Include the original anxiety, insomnia or other condition. The assessment should explain which needs are being addressed and whether addiction-focused therapy is indicated.

Prepare the full history across clinicians and countries. Include exact formulations, how the medicine is actually taken, previous changes and any withdrawal complications. Describe alcohol, opioids and other sedatives. If records disagree, ask the responsible professional to clarify them. A private residence cannot compensate for an incomplete medical picture.

PUK Zurich describes withdrawal treatment within a range of addiction and dual-diagnosis services. Its published target group and cantonal preferences mean eligibility needs individual checking. HUG’s Geneva-area pathways include outpatient addiction care and planned hospital transition services. These are clinical options to investigate, not guarantees of a particular admission, language, funding decision or accommodation standard. [3] [4]

For many Swiss residents, remaining close to established clinicians may make an extended medical plan more workable. A Mallorca stay needs a separate justification: what therapeutic work requires that environment, and how will the Swiss medical connection be preserved? A program should be able to answer both questions rather than treat geographical distance as the treatment itself.

Stopping benzodiazepines abruptly or reducing them too rapidly can cause dangerous withdrawal, including seizures. Alcohol and opioids can add serious interaction risks. Do not stop a prescription to prepare for admission or make an independent substitution for travel. The responsible clinician should assess the required support and explain the medical plan. [6]

The joint guideline recognizes outpatient management for many people and higher levels of care when risk or instability makes that necessary. Previous severe withdrawal, other substance use, medical conditions and psychiatric needs all matter. Ask why the proposed setting is appropriate for the current situation and how the team would respond to deterioration. A low number of residents is not evidence of emergency capability. [1]

A seizure, severe confusion, breathing difficulty, suspected overdose or immediate danger needs urgent local medical attention. Do not postpone that assessment while comparing residential programs abroad. Once immediate needs are managed, clinicians can help determine whether the next stage should be medical follow-up, addiction treatment, residential therapy or a combination. [6]

If addiction is present, the therapy plan should address the pattern of use and its context. Ask how the program explores moments of extra use, access to medication, secrecy, distress and consequences at home or work. The work should help the person develop practical responses, not simply repeat that they need more willpower. Goals should be understandable and connected to the history discussed in assessment.

For dependence without addiction, the psychological needs may be different. Someone may need help managing fear, rebuilding confidence and maintaining function during a medically supervised change. The presence of difficult symptoms should not be dismissed as resistance. Ask how the therapist and prescriber communicate so that medical and psychological explanations do not become competing demands on the client. [1]

Anxiety and sleep still require care. The original symptoms may continue, and changes during treatment need clinical interpretation. For chronic insomnia, ask about appropriate evidence-based sleep treatment, including CBT-I when indicated. NHLBI identifies it as a usual first approach, but availability at the selected provider must be checked. Comfort, bodywork and a quiet bedroom do not establish a specialist sleep service. [7]

Identify the clinician who will take responsibility after any stay and ask whether the proposed plan is acceptable. The receiving professional may need earlier records, a medication summary and direct discussion with the treating team. A discharge letter alone does not prove that ongoing prescribing has been accepted. This matters particularly when several clinicians have been involved or the person divides time between countries.

Confirm the language of care and the practical meaning of aftercare. Is it psychotherapy, medical review, care coordination or another service? Who delivers it, and from where? The answer should be specific to the person’s home canton and circumstances. Do not assume that a provider abroad can continue every service remotely or that a general aftercare offer replaces local medical care.

If insurance is relevant, request a decision for the specific service before relying on reimbursement. A Swiss clinical pathway and a private overseas residence may be assessed differently by a payer. Ask the provider to state the payment obligations clearly. COGNIFUL is generally self-pay, does not bill insurers directly and cannot guarantee reimbursement. [5]

COGNIFUL is located in Mallorca. Its prescription-medication pathway includes review of benzodiazepine concerns without assuming every case is addiction or requires rehab. The assessment considers medical stability, current use, other conditions and whether the shared residential format can meet the person’s needs. Where medical withdrawal management or another level of care is required first, that should determine the sequence. [2] [8]

COGNIFUL Premier and Premier Plus use a residence for a maximum of four clients at any time. Each client has a private suite. Clinical and bodywork sessions are individual, while the residence, chef, personal manager, other holistic sessions, excursions and activities are shared. Ask whether that combination of personal clinical work and shared daily life is suitable. Capacity alone does not establish staffing ratios, a fixed therapy schedule or a medical advantage. [5]

The residential proposal should identify the work relevant to this person. It may involve coping with distress, relationships, anxiety or harmful medication use, depending on assessment. Confirm who is expected to contribute and how progress will be reviewed. Any essential sleep, pain, prescribing or withdrawal service must be identified explicitly. COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. Clinical assessment determines the appropriate care plan and setting. In some cases, treatment may begin with an initial 1–3 days in a partner hospital for observation and stabilization before continuing at COGNIFUL. The pathway is planned around each person’s medical needs. [8] The medical plan, prescribing responsibilities and any additional specialist support are confirmed individually.

COGNIFUL Premier and Premier Plus both include assessment, an individual treatment plan and continuing-care planning. Plus adds individual therapeutic work, family and transition work, and three months of aftercare. Base-program follow-up is individually agreed. COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. [5] View program fees

Ask how the program difference relates to actual needs. A family may need help understanding the distinction between dependence and addiction; the person may need a carefully planned return to work or several clinicians. The proposal should explain the work offered rather than rely on a general promise of more support. It should also confirm duration, total cost, inclusions and possible additional charges.

Before the return to Switzerland, establish accepted appointments and a usable medical handover. COGNIFUL’s continuing-care planning can prepare that transition, but follow-up delivery depends on the program and individual agreement. Prescribing responsibilities, external appointments and remote-care limits must be clear. An aftercare period should not be mistaken for guaranteed cross-border medical provision. [9]

Agree who may receive clinical information and who handles practical arrangements. A partner, assistant or family office may be involved in logistics without attending medical discussions. The person should have a private opportunity to explain symptoms and concerns. Clear boundaries can reduce pressure to present a reassuring account rather than an accurate one.

Discuss work requirements with the appropriate clinician, especially when duties involve driving, safety or complex decisions. A provider’s internet access is not evidence that continuing work is clinically appropriate. The plan should consider current functioning and realistic demands after discharge. These practical decisions should support treatment rather than turn the residence into a different place from which to maintain the same pressures.

• What evidence supports a diagnosis of addiction rather than dependence alone?
• Which medical service manages any withdrawal risk and continuing prescription?
• Why is the proposed setting suitable now, and what could require a change?
• How are the original anxiety or sleep needs addressed?
• Who in Switzerland has accepted the next stage of care?

Does dependence necessarily mean I have an addiction?

No. The two concepts differ, although they can overlap. Assessment should consider control, harm, actual use and the reason for treatment. The recommendation should reflect those findings rather than the medication name alone. [1]

Can treatment continue after a residential stay ends?

It may need to. Some benzodiazepine-related medical plans extend beyond a short admission. Confirm who will continue the work and how decisions will be reviewed instead of assuming discharge means the process is complete. [1]

Is COGNIFUL located in Switzerland?

No Swiss residence is established here. COGNIFUL’s verified residential setting is in Mallorca, Spain. Swiss residents can inquire about suitability with local continuity planned around that overseas location. [5]

Should medication be changed before arrival?

Only through the responsible clinical plan. Do not stop or alter benzodiazepines independently to prepare for a stay; abrupt withdrawal can be dangerous. Share accurate information with the assessment team. [6]

COGNIFUL admissions can explain its Mallorca programs and the information needed to assess a benzodiazepine concern. Describe current care in Switzerland, actual medication use and any difficult withdrawal history. The next step should make the medical responsibilities and potential residential role explicit. [5]

1. Joint Clinical Practice Guideline on Benzodiazepine Tapering — American Society of Addiction Medicine and partner societies.
2. Prescription medication concerns and residential treatment — COGNIFUL.
3. Addiction disorders and dual diagnoses — Psychiatric University Hospital Zurich.
4. Addictology service care options — Geneva University Hospitals.
5. COGNIFUL programs, fees, admissions and suitability — COGNIFUL.
6. Benzodiazepine safety communication — US Food and Drug Administration.
7. Insomnia treatment — National Heart, Lung, and Blood Institute.
8. Clinical scope, suitability and care coordination — COGNIFUL.
9. Reintegration and continuing care — COGNIFUL.

Primary clinical and provider pages accessed October 18, 2026. Individual services, admission and fees should be confirmed directly.